The Medication Patterns of Spinocerebellar Ataxia Type 3 Mutation Carriers Enrolled in the ESMI Cohort.

CNS Drugs · 2026 · PMC12855365 · PMID 41105366

Europe PMC DOI

hedged sentence

0.0503

closest p · 1.0× alpha

0.0503

boldest claim

The sentences

showed a trendp = 0.0503so close (0.05 < p ≤ 0.1)

Among these, only anti-Parkinson drugs showed a trend toward increased use compared with moderately severe ataxia (18.7% versus 33.9%, p = 0.0503).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.